Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of two regimens for cancer anorexia/cachexia syndrome
2010-019831-36Phase 3Active
- Sponsor
- Azienda Ospedaliero Universitaria di Cagliari
- Start
- Jun 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of levocarnitine, celecoxib, carbocisteine and megestrol in cancer anorexia-cachexia syndrome (CACS) (2 arms), sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoints: Change in lean body mass, Change in resting energy expenditure and 2 more. Started Jun 2010; status: active.
02
Drugs
levocarnitinecelecoxibcarbocisteinemegestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2010-019831-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019831-36.